Reflux Esophagitis Phase III Study (Maintenance Treatment)

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (213 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: recurrencereceivingpatientstreatment withperformed
  Phrases that lowered it: once dailythe efficacyoral administrationand safetysafety of
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Minimum age: 20 (lowers risk) · Who can join
• Responsible party: not given (raises risk) · Design
• Drug's FAERS reports with a death: 9.0% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past termination rate: 7.5% (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 207 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 77.2% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 372 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 32040 (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus) NCT01669811 · started 2012 · scored riskier than 6% of active trials completed
• Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Esophagitis NCT04022096 · started 2019 · scored riskier than 9% of active trials completed
• Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) NCT00658775 · started 2008 · scored riskier than 21% of active trials completed
• Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) NCT00838526 · started 2008 · scored riskier than 22% of active trials completed
• Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) NCT00839306 · started 2008 · scored riskier than 23% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.